Please assess the completion status of the following clinical trial:

Trial Title: Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetic neuropathy~* Age 18-80~* Willing to temporarily discontinue gabapentin or monoamine reuptake inhibitors upon entry into the study~Exclusion Criteria:~* Pregnancy~* Allergy to study medications~* Uncontrolled narrow-angle glaucoma~* Currently being treatment with thioridazine (Mellaril)~* Unstable medical conditions including cardiac, pulmonary, renal or hepatic diseases~* Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: ACTIVE_COMPARATOR): Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
- Duloxetine (Type: ACTIVE_COMPARATOR): Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
- Donepezil + Duloxetine (Type: ACTIVE_COMPARATOR): Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
- Placebo (Type: PLACEBO_COMPARATOR): Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).